Literature DB >> 33505468

Autoimmune Factor V Deficiency That Took 16 Years to Diagnose due to Pseudodeficiency of Multiple Coagulation Factors.

Takaaki Kato1, Takaya Hanawa1, Mea Asou1, Tomohiko Asakawa1, Hisashi Sakamaki2, Makoto Araki1.   

Abstract

A 70-year-old man presented to our hospital with intramuscular hemorrhage in the right thigh. He had exhibited a tendency to bleed for the last 16 years and had visited several medical institutions, but no diagnosis had been made. Since the risk of sudden bleeding was assumed to be high due to his age, we decided to examine him in our department. A coagulation abnormality with prothrombin time-international normalized ratio (PT-INR) of 4.5 and activated partial thromboplastin time (aPTT) of 99.6 seconds was observed, but the platelet count, fibrinogen, and PIVKAII were within normal limits. Coagulation activities of factor V, VII, VIII, IX, X, XI, XII, and XIII were all reduced. Anti-factor VIII and IX antibodies which were measured by the Bethesda method, lupus anti-coagulant (diluted Russell snake venom time method) and anti-cardiolipin antibody were also positive. The results of these tests were comparable to those undertaken 15 years ago when they were scrutinized at the university hospital. We suspected the presence of anti-factor V antibodies because there was a dissociation between the thrombotest values measured and those calculated from the PT-INR. Moreover, cross-mixing test showed an immediate inhibitor pattern. Subsequently, factor V antibodies were confirmed by the immunoblot method and the diagnosis of autoimmune factor V deficiency was made. When factor V, which is downstream of the coagulation cascade, is inhibited, coagulation test using the one-stage clotting method shows a pseudolow value. Therefore, extensive abnormalities of coagulation factor activity and inhibitor assay should be interpreted with caution, and the presence of a high titer of factor V inhibitor should be considered.
Copyright © 2021 Takaaki Kato et al.

Entities:  

Year:  2021        PMID: 33505468      PMCID: PMC7815411          DOI: 10.1155/2021/4657501

Source DB:  PubMed          Journal:  Case Rep Med


  13 in total

1.  [Relationship between prothrombin time international normalized ratio and thrombo test (%)].

Authors:  Y Numata; Y Ogata; K Arao; Y Mizumasa; T Wakita; H Haruguchi; H Araki; T Tsuji; K Mawatari; K Shimada
Journal:  J Cardiol       Date:  2001-12       Impact factor: 3.159

Review 2.  Laboratory tests for the antiphospholipid syndrome: current concepts.

Authors:  Freda Passam; Steven Krilis
Journal:  Pathology       Date:  2004-04       Impact factor: 5.306

Review 3.  How we diagnose the antiphospholipid syndrome.

Authors:  Bill Giannakopoulos; Freda Passam; Yiannis Ioannou; Steven A Krilis
Journal:  Blood       Date:  2008-08-28       Impact factor: 22.113

4.  Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.

Authors:  Peter W Collins; Sybil Hirsch; Trevor P Baglin; Gerard Dolan; John Hanley; Michael Makris; David M Keeling; Ri Liesner; Simon A Brown; Charles R M Hay
Journal:  Blood       Date:  2006-10-17       Impact factor: 22.113

Review 5.  Factor V and thrombotic disease: description of a janus-faced protein.

Authors:  Gerry A F Nicolaes; Björn Dahlbäck
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-04-01       Impact factor: 8.311

6.  Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations.

Authors:  Michael Kalafatis; Paolo Simioni; Daniela Tormene; Daniel O Beck; Sonia Luni; Antonio Girolami
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

7.  A high titer of acquired factor V inhibitor in a hemodialysis patient who developed arterial thrombosis.

Authors:  Hina Ogawa; Masayoshi Souri; Kazunori Kanouchi; Tsukasa Osaki; Rie Ohkubo; Tomoko Kawanishi; Sachiko Wakai; Keita Morikane; Akitada Ichinose
Journal:  Int J Hematol       Date:  2018-11-16       Impact factor: 2.490

8.  High Titer of Acquired Factor V Inhibitor Presenting with a Pseudo-deficiency of Multiple Coagulation Factors.

Authors:  Keiichi Nakata; Shuji Ueda; Hitomi Matsunaga; Fuka Mima; Hiroki Ueda; Aya Yoshioka; Sayoko Kaneko; Kazushi Maruo; Shayne Morris; Sayoko Yonemoto; Daisuke Hayashi; Naohiko Fujii; Hiroyuki Narahara; Yoshiaki Inui; Sumio Kawata
Journal:  Intern Med       Date:  2017-11-01       Impact factor: 1.271

9.  Building an immune-mediated coagulopathy consensus: early recognition and evaluation to enhance post-surgical patient safety.

Authors:  Paul Ness; Michael Creer; George M Rodgers; Joseph J Naoum; Kenneth Renkens; Stacy A Voils; W Allan Alexander
Journal:  Patient Saf Surg       Date:  2009-05-22

10.  A discrepancy between prothrombin time and Normotest (Hepaplastintest) results is useful for diagnosis of acquired factor V inhibitors.

Authors:  Yasuko Kadohira; Shinya Yamada; Tomoe Hayashi; Eriko Morishita; Hidesaku Asakura; Akitada Ichinose
Journal:  Int J Hematol       Date:  2018-04-02       Impact factor: 2.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.